Cas:35099-99-1 lanthanum nitrate manufacturer & supplier

Chemical Name:lanthanum nitrate

CAS.NO:35099-99-1

Synonyms:Lanthanum(III) nitrate,hexahydrate (1:3:6);lanthanum(3+) trinitrate;LS-359;Lanthanum nitrate solution;Nitric acid,lanthanum(3+) salt,hexahydrate

Molecular Formula:LaN₃O₉

Molecular Weight:324.92000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:206.64000

Exact Mass:324.87000

LogP:0.85230

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Lanthanum(III) nitrate,hexahydrate (1:3:6) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Nitric acid,lanthanum(3+) salt,hexahydrate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,LS-359 Use and application,lanthanum(3+) trinitrate technical grade,usp/ep/jp grade.

Related News: Soliris, first approved for generalized myasthenia gravis (gMG) in 2017, carries a list price of about $470,000 annually. But to ICER, that cost is “well beyond typical thresholds.” [(η6-hexamethylbenzene)-(1,5-cyclooctadiene)-rhodium] hexafluorophosphate manufacturers Wavelength, a more than 30-year-old firm based in Petah Tikva, launched its API CDMO business in early 2020 and currently sports more than 250 customers from 50 countries. 5β,8α-dibenzyloxy-2β-methyl-1β-[3-(1-ethoxyethoxy)propyl]-1,2,4aα,5,6,7,8,8aβ-octahydronaphthalene suppliers Wavelength, a more than 30-year-old firm based in Petah Tikva, launched its API CDMO business in early 2020 and currently sports more than 250 customers from 50 countries. diethyl (2-(benzo[d][1,3]dioxol-5-yl)-2-oxoethyl)phosphonate vendor & factory The site, near Dehradun in the Himalayan foothills, will have a capacity to produce 1 billion units annually, delivering vials filled with liquid and powder, lyophilized vials, dental cartridges and prefilled syringes. ,Soliris, first approved for generalized myasthenia gravis (gMG) in 2017, carries a list price of about $470,000 annually. But to ICER, that cost is “well beyond typical thresholds.”